154 related articles for article (PubMed ID: 15179321)
1. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Cetkovic-Cvrlje M; Uckun FM
Arch Immunol Ther Exp (Warsz); 2004; 52(2):69-82. PubMed ID: 15179321
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.
Cetkovic-Cvrlje M; Tibbles HE
Curr Pharm Des; 2004; 10(15):1767-84. PubMed ID: 15180539
[TBL] [Abstract][Full Text] [Related]
3. Regulation of JAK3 expression and activation in human B cells and B cell malignancies.
Tortolani PJ; Lal BK; Riva A; Johnston JA; Chen YQ; Reaman GH; Beckwith M; Longo D; Ortaldo JR; Bhatia K; McGrath I; Kehrl J; Tuscano J; McVicar DW; O'Shea JJ
J Immunol; 1995 Dec; 155(11):5220-6. PubMed ID: 7594533
[TBL] [Abstract][Full Text] [Related]
4. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
5. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
[TBL] [Abstract][Full Text] [Related]
6. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
7. JAK3 inhibitors in organ transplantation and autoimmune disease.
Xiong Z; Ma A; Chen H
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):75-81. PubMed ID: 19832695
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
9. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
10. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice.
Han HS; Jun HS; Utsugi T; Yoon JW
J Autoimmun; 1997 Jun; 10(3):299-307. PubMed ID: 9218758
[TBL] [Abstract][Full Text] [Related]
11. JAK protein kinase inhibitors.
Thompson JE
Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
13. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha.
Doucet C; Giron-Michel J; Canonica GW; Azzarone B
Eur J Immunol; 2002 Sep; 32(9):2437-49. PubMed ID: 12207328
[TBL] [Abstract][Full Text] [Related]
14. Defective lymphoid development in mice lacking Jak3.
Nosaka T; van Deursen JM; Tripp RA; Thierfelder WE; Witthuhn BA; McMickle AP; Doherty PC; Grosveld GC; Ihle JN
Science; 1995 Nov; 270(5237):800-2. PubMed ID: 7481769
[TBL] [Abstract][Full Text] [Related]
15. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.
Kirken RA; Erwin RA; Taub D; Murphy WJ; Behbod F; Wang L; Pericle F; Farrar WL
J Leukoc Biol; 1999 Jun; 65(6):891-9. PubMed ID: 10380915
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.
Säemann MD; Zeyda M; Stulnig TM; Böhmig GA; Wekerle T; Hörl WH; Zlabinger GJ
Transpl Int; 2004 Oct; 17(9):481-9. PubMed ID: 15368094
[TBL] [Abstract][Full Text] [Related]
17. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
Vassilev AO; Tibbles HE; DuMez D; Venkatachalam TK; Uckun FM
Curr Drug Targets; 2006 Mar; 7(3):327-43. PubMed ID: 16515530
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of Janus kinases.
Pesu M; Laurence A; Kishore N; Zwillich SH; Chan G; O'Shea JJ
Immunol Rev; 2008 Jun; 223():132-42. PubMed ID: 18613833
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract][Full Text] [Related]
20. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]